Trials / Unknown
UnknownNCT05672979
Prospective triAl of Modified Treat-and-extend Regimens With BroLucizumab in pachychOroid Neovasculopathy
- Status
- Unknown
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 36 (estimated)
- Sponsor
- Yeungnam University College of Medicine · Academic / Other
- Sex
- All
- Age
- 19 Years
- Healthy volunteers
- Accepted
Summary
PNV is a recently described clinical entity; therefore, studies about treatment efficacy and safety are few, with limited follow-up and a small number of participants. Treatment is based on intravitreal anti-VEGF injections, similar to neovascular AMD. According to reported results however, efficacy seems different in fluid reabsorption among anti-VEGF agents. A newly developed anti-VEGF molecule for the treatment of neovascular AMD, brolucizumab, has been shown in clinical studies to have longer durability and improved visual outcomes using a q12-week regimen, thus having the potential to reduce treatment burden and serve as an important therapeutic tool in the management of neovascular AMD. Nevertheless, there have been no reports specifically focusing on the efficacy of brolucizumab in the treatment of PNV. The purpose of this study is to evaluate the efficacy and safety profile of the modified treat-and-extend regimen to 64 weeks by intravitreal brolucizumab injection in eyes with treatment-naive pachychoroid neovasculopathy (PNV) patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Brolucizumab Injection [Beovu] | brolucizumab 6mg intravitreal injection |
Timeline
- Start date
- 2023-01-01
- Primary completion
- 2024-12-31
- Completion
- 2024-12-31
- First posted
- 2023-01-05
- Last updated
- 2023-01-05
Source: ClinicalTrials.gov record NCT05672979. Inclusion in this directory is not an endorsement.